Literature DB >> 16877298

Clinical symptoms and the odds of human T-cell lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) in healthy virus carriers: application of best-fit logistic regression equation based on host genotype, age, and provirus load.

Hirohisa Nose1, Mineki Saito, Koichiro Usuku, Amir H Sabouri, Toshio Matsuzaki, Ryuji Kubota, Nobutaka Eiraku, Yoshitaka Furukawa, Shuji Izumo, Kimiyoshi Arimura, Mitsuhiro Osame.   

Abstract

The authors have previously developed a logistic regression equation to predict the odds that a human T-cell lymphotropic virus type 1 (HTLV-1)-infected individual of specified genotype, age, and provirus load has HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in southern Japan. This study evaluated whether this equation is useful predictor for monitoring asymptomatic HTLV-1-seropositive carriers (HCs) in the same population. The authors genotyped 181 HCs for each HAM/TSP-associated gene (tumor necrosis factor [TNF]-alpha-863A/C, stromal cell-derived factor 1 (SDF-1) +801G/A, human leukocyte antigen [HLA]-A*02, HLA-Cw*08, HTLV-1 tax subgroup) and measured HTLV-1 provirus load in peripheral blood mononuclear cells using real-time polymerase chain reaction (PCR). Finally, the odds of HAM/TSP for each subject were calculated by using the equation and compared the results with clinical symptoms and laboratory findings. Although no clear difference was seen between the odds of HAM/TSP and either sex, family history of HAM/TSP or adult T-cell lenkemia (ATL), history of blood transfusion, it was found that brisk patellar deep tendon reflexes, which suggest latent central nervous system compromise, and flower cell-like abnormal lymphocytes, which is the morphological characteristic of ATL cells, were associated with a higher odds of HAM/TSP. The best-fit logistic regression equation may be useful for detecting subclinical abnormalities in HCs in southern Japan.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877298     DOI: 10.1080/13550280600827336

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  25 in total

1.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

Review 2.  The immune response to HTLV-I.

Authors:  C R Bangham
Journal:  Curr Opin Immunol       Date:  2000-08       Impact factor: 7.486

3.  Increased replication of HTLV-I in HTLV-I-associated myelopathy.

Authors:  M Yoshida; M Osame; H Kawai; M Toita; N Kuwasaki; Y Nishida; Y Hiraki; K Takahashi; K Nomura; S Sonoda
Journal:  Ann Neurol       Date:  1989-09       Impact factor: 10.422

4.  Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis.

Authors:  Mineki Saito; Itsuro Higuchi; Akiko Saito; Shuji Izumo; Koichiro Usuku; Charles R M Bangham; Mitsuhiro Osame
Journal:  J Infect Dis       Date:  2002-10-07       Impact factor: 5.226

5.  HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy.

Authors:  K J Jeffery; K Usuku; S E Hall; W Matsumoto; G P Taylor; J Procter; M Bunce; G S Ogg; K I Welsh; J N Weber; A L Lloyd; M A Nowak; M Nagai; D Kodama; S Izumo; M Osame; C R Bangham
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection.

Authors:  K J Jeffery; A A Siddiqui; M Bunce; A L Lloyd; A M Vine; A D Witkover; S Izumo; K Usuku; K I Welsh; M Osame; C R Bangham
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

7.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

8.  Influence of human T lymphotrophic virus type I on cryptogenic fibrosing alveolitis - HTLV-I associated fibrosing alveolitis: proposal of a new clinical entity.

Authors:  W Matsuyama; M Kawabata; A Mizoguchi; F Iwami; J Wakimoto; M Osame
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

9.  Immunohistochemical characteristics of polymyositis in patients with HTLV-I-associated myelopathy and HTLV-I carriers.

Authors:  I Higuchi; E S Montemayor; S Izumo; M Inose; M Osame
Journal:  Muscle Nerve       Date:  1993-05       Impact factor: 3.217

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  3 in total

1.  Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I-associated myelopathy.

Authors:  Fujio Umehara; Hirohisa Nose; Mineki Saito; Michinari Fukuda; Mieko Ogino; Tomoko Toyota; Tomoaki Yuhi; Kimiyoshi Arimura; Mitsuhiro Osame
Journal:  J Neurovirol       Date:  2007-06       Impact factor: 2.643

2.  Prognosis Markers for Monitoring HTLV-1 Neurologic Disease.

Authors:  Gabriela Prates; Tatiane Assone; Marcelo Corral; Maíra P M Baldassin; Tatiane Mitiko; Flávia C Silva Sales; Michel E Haziot; Jerusa Smid; Luiz A M Fonseca; Fernanda de Toledo Gonçalves; Augusto C Penalva de Oliveira; Jorge Casseb
Journal:  Neurol Clin Pract       Date:  2021-04

3.  Estimation of HTLV-1 vertical transmission cases in Brazil per annum.

Authors:  Carolina Rosadas; Bassit Malik; Graham P Taylor; Marzia Puccioni-Sohler
Journal:  PLoS Negl Trop Dis       Date:  2018-11-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.